TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Key Highlights
- ➤TRexBio (TRXB) completed a $133.5 million IPO, extending cash runway into second half of 2029
- ➤TRB-061 Phase 1a results showed reproducible Treg activation and expansion, supporting proof of mechanism
- ➤TRB-061 Phase 1b atopic dermatitis topline data expected in mid-2027
- ➤TRB-071 Phase 1 trial initiation expected in first half of 2027, subject to regulatory allowance
- ➤Third-quarter net loss widened to $13.2 million from $7.9 million year over year
Expert Statements
Johnston Erwin, Chief Executive Officer of TRexBio
“Our approach begins with understanding how regulatory T cells function in human tissues and using those insights to develop medicines intended to address the underlying immune dysfunction in disease.”
Johnston Erwin, Chief Executive Officer of TRexBio
“The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach.”
Johnston Erwin, Chief Executive Officer of TRexBio
“We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis.”
Johnston Erwin, Chief Executive Officer of TRexBio
“With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”
* Positive Phase 1a results for TRB-061 support proof of mechanism, with topline Phase 1b data in atopic dermatitis expected in mid-2027 * TRB-071 advancing through IND-enabling studies, with Phase 1 trial initiation expected in the first half of 2027 * Completed a $133.5 million initial public offering in October 2026, extending expected cash runway into the second half of 2029 SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. ("TRexBio") (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today reported financial results for the third quarter ended September 30, 2026, and provided recent business highlights and anticipated development milestones.
“Our approach begins with understanding how regulatory T cells function in human tissues and using those insights to develop medicines intended to address the underlying immune dysfunction in disease,” said Johnston Erwin, Chief Executive Officer of TRexBio. “The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis. With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”
Get started
Create a free account to read the full story.